Ekso Bionics Holdings, Inc. (EKSO): Price and Financial Metrics

Ekso Bionics Holdings, Inc. (EKSO): $0.71

0.02 (-2.42%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

EKSO Price/Volume Stats

Current price $0.71 52-week high $1.88
Prev. close $0.73 52-week low $0.62
Day low $0.70 Volume 14,200
Day high $0.75 Avg. volume 37,047
50-day MA $0.97 Dividend yield N/A
200-day MA $1.36 Market Cap 9.84M

EKSO Stock Price Chart Interactive Chart >

EKSO Stock Summary

  • EKSO BIONICS HOLDINGS INC's market capitalization of $9,526,796 is ahead of merely 5.79% of US-listed equities.
  • With a price/sales ratio of 0.61, EKSO BIONICS HOLDINGS INC has a higher such ratio than merely 21.78% of stocks in our set.
  • With a year-over-year growth in debt of 247.36%, EKSO BIONICS HOLDINGS INC's debt growth rate surpasses 95.17% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to EKSO BIONICS HOLDINGS INC are ASPN, CMRA, SGHT, OMCL, and BDSX.
  • Visit EKSO's SEC page to see the company's official filings. To visit the company's web site, go to www.eksobionics.com.

EKSO Valuation Summary

  • In comparison to the median Healthcare stock, EKSO's price/earnings ratio is 102.25% lower, now standing at -0.6.
  • Over the past 115 months, EKSO's price/earnings ratio has gone up 2.2.

Below are key valuation metrics over time for EKSO.

Stock Date P/S P/B P/E EV/EBIT
EKSO 2023-09-22 0.6 0.5 -0.6 -0.2
EKSO 2023-09-21 0.6 0.5 -0.6 -0.2
EKSO 2023-09-20 0.6 0.6 -0.6 -0.3
EKSO 2023-09-19 0.7 0.6 -0.6 -0.3
EKSO 2023-09-18 0.7 0.6 -0.6 -0.3
EKSO 2023-09-15 0.6 0.6 -0.6 -0.3

EKSO Growth Metrics

    Its year over year cash and equivalents growth rate is now at -26.97%.
  • Its 2 year net cashflow from operations growth rate is now at -8.48%.
  • Its year over year revenue growth rate is now at 27.65%.
EKSO's revenue has moved up $6,266,000 over the prior 67 months.

The table below shows EKSO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 13.437 -14.119 -14.765
2022-06-30 13.157 -14.004 -12.419
2022-03-31 11.903 -13.362 -10.714
2021-12-31 11.246 -11.156 -9.764
2021-09-30 9.424 -9.821 -10.877
2021-06-30 9.272 -8.616 -6.467

EKSO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EKSO has a Quality Grade of D, ranking ahead of 7.97% of graded US stocks.
  • EKSO's asset turnover comes in at 0.242 -- ranking 100th of 104 Machinery stocks.
  • MOG.A, DRQ, and CECE are the stocks whose asset turnover ratios are most correlated with EKSO.

The table below shows EKSO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.242 0.615 -1.072
2021-03-31 0.303 0.608 -2.750
2020-12-31 0.426 0.571 -2.648
2020-09-30 0.489 0.538 -2.401
2020-06-30 0.529 0.511 -2.663
2020-03-31 0.556 0.493 -1.145

EKSO Price Target

For more insight on analysts targets of EKSO, see our EKSO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.00 Average Broker Recommendation 1.5 (Moderate Buy)

Ekso Bionics Holdings, Inc. (EKSO) Company Bio


Founded in 2005 in Richmond, California, Ekso Bionics Holdings Inc employs approximately 92 people that design, develop, and sell wearable bionic human exoskeletons that have applications in healthcare, industrial, military, and consumer markets. The company’s first product, HULC was developed for the military in partnership with Lockheed Martin, enhancing soldier capabilities to allow them to carry heavier loads over further distances. The EksoNR is currently the only FDA-cleared exoskeleton for treatment of ABI, helping physical therapists, physiatrists, and doctors to clinically rehabilitate patients. The company’s CEO is Jack Peurach, who served as Executive Vice President, Products for SunPower Corp before becoming Ekso’s Chief Executive Officer.


EKSO Latest News Stream


Event/Time News Detail
Loading, please wait...

EKSO Latest Social Stream


Loading social stream, please wait...

View Full EKSO Social Stream

Latest EKSO News From Around the Web

Below are the latest news stories about EKSO BIONICS HOLDINGS INC that investors may wish to consider to help them evaluate EKSO as an investment opportunity.

Q2 2023 Ekso Bionics Holdings Inc Earnings Call

Q2 2023 Ekso Bionics Holdings Inc Earnings Call

Yahoo | July 28, 2023

Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -10.71% and 8.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 27, 2023

Ekso Bionics Reports Record Revenues of $4.7 Million in Second Quarter 2023

Record number of EksoHealth devices booked in second quarter 2023SAN RAFAEL, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2023. Recent Highlights and Accomplishments Achieved record revenues of $4.7 million in the second quarter of 2023, an increase of 36% year-over-yearBooked a total of

Yahoo | July 27, 2023

Ekso Bionics to Report Second Quarter 2023 Financial Results on July 27, 2023

SAN RAFAEL, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2023 after the close of trading on Thursday, July 27, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business develop

Yahoo | July 20, 2023

Ekso Bionics Announces 61% Increase in First Quarter 2023 Revenues

Highest Quarterly Revenues in Company History SAN RAFAEL, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2023. Recent Highlights and Accomplishments Achieved record revenues of $4.1 million in the first quarter of 2023, up 61% from the first quarter of 2022Delivered products acr

Yahoo | April 27, 2023

Read More 'EKSO' Stories Here

EKSO Price Returns

1-mo -24.32%
3-mo -50.35%
6-mo -56.97%
1-year -54.49%
3-year -84.12%
5-year -97.98%
YTD -40.34%
2022 -55.09%
2021 -56.77%
2020 4.52%
2019 -68.47%
2018 -41.78%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!